The deal extends reach of Claris’s products in Europe, North America and Australia.
Pfizer will undertake the commercialisation of the products that have gone off-patent in the western markets. The move will expand Pfizer’s generic drugs portfolio.
Claris manufactures and markets injectables with emphasis on New Drug Delivery Systems for treatment of critical illnesses and diseases.